Not theory. Not consulting frameworks. Hands-on guidance from someone who has raised the capital, navigated FDA, and delivered the exit.
Gary serves as an independent board director and board observer for PE-backed and growth-stage healthcare AI companies. He brings operating credibility — not just governance theory — having sat in the CEO chair across five venture-backed companies.
Retainer-based engagements calibrated to where your company is in the journey. Gary works directly with founders and CEOs on the highest-leverage strategic challenges — from go-to-market architecture to regulatory roadmap to enterprise positioning.
Gary has been through the full capital lifecycle — from early-stage venture to late-stage structured rounds to PE-backed growth financing. He helps healthcare AI companies build the narrative, materials, and process to close their next round.
Structured to fit where your company is — not a one-size-fits-all retainer.
Formal board seat or observer role. Quarterly board meetings plus ongoing availability to the CEO and management team. Typically structured as equity + minimal cash retainer for early-stage; cash + equity for growth-stage.
Monthly retainer with defined hours and deliverables. Includes regular CEO calls, project-based work (fundraising prep, regulatory strategy, GTM), and ad-hoc availability. 3–12 month initial term.
Scoped engagements for specific needs — fundraising process support, board preparation, FDA strategy, or M&A diligence. Defined scope, timeline, and deliverables. Ideal for companies not yet ready for a full retainer.
Gary focuses on companies where his specific background creates maximum leverage.
Private equity firms with a thesis around acquiring and scaling AI-based digital endpoint and health companies. Gary serves as an operating partner or board director to portfolio companies, providing hands-on guidance and credibility with management teams.
Series A–C healthcare AI founders navigating FDA clearance, enterprise go-to-market, or their first institutional raise. Gary has been in that seat five times and can compress the learning curve significantly.
Companies at the intersection of AI, wearables, clinical decision support, and regulated digital biomarkers. If your product touches physiology, patient data, or clinical workflow — Gary understands the landscape.
Life sciences companies and health systems looking for an independent voice on AI strategy, digital biomarker partnerships, and precision medicine program development. Gary's pharma engagement experience (Lilly and others) informs his advisory.
Every engagement starts with a conversation. No commitment required.